List of Excipients in Branded Drug FEMCON FE

FEMCON FE Excipient Strategy and Commercial Opportunities

Last updated: August 30, 2026

Femcon Fe is a chewable combined oral contraceptive containing norethindrone 0.4 mg and ethinyl estradiol 0.035 mg in 21 active tablets, followed by seven ferrous fumarate tablets. Its commercial differentiation was the chewable dosage form, not a novel active ingredient or a high-value excipient platform. The strongest opportunity is a modernized chewable generic or reformulated oral contraceptive with improved taste, lower tablet mass, stronger moisture protection, and more convenient packaging.

What is Femcon Fe and how does its dosage form work?

Femcon Fe is a 28-day oral contraceptive regimen. The active tablets contain norethindrone and ethinyl estradiol. The seven non-hormonal tablets contain ferrous fumarate and support regimen continuity rather than contraceptive activity.[1]

Attribute	Femcon Fe
Active ingredients	Norethindrone and ethinyl estradiol
Hormonal strength	0.4 mg norethindrone / 0.035 mg ethinyl estradiol
Dosage form	Chewable tablet
Pack structure	21 active tablets plus seven ferrous fumarate tablets
Therapeutic class	Combined hormonal contraceptive
Administration	Chewed or swallowed according to product labeling
Primary differentiation	Chewability and regimen packaging
Regulatory pathway	Abbreviated or full application depending on the product and sponsor
Principal commercial substitutes	Conventional norethindrone/ethinyl estradiol tablets, chewable generics, and other combined oral contraceptives

Femcon Fe is technically distinct from products containing norethindrone acetate. A generic development program must match the reference product’s active ingredient, strength, dosage form, route, and relevant formulation characteristics.

What excipients are used in Femcon Fe?

Public product labeling identifies conventional tablet excipients for the active and ferrous fumarate tablets. The listed excipient system includes lactose monohydrate, microcrystalline cellulose, magnesium stearate, povidone, sodium starch glycolate, talc, and flavoring components.[1]

The exact qualitative and quantitative formulation should be confirmed against the current reference-product labeling and the FDA-approved product record before regulatory or freedom-to-operate decisions. Excipient selection affects taste, tablet hardness, disintegration, dissolution, manufacturability, and patient acceptance.

Excipient-function map

Excipient or excipient class	Likely function in a chewable tablet	Development relevance
Lactose monohydrate	Diluent and mouthfeel modifier	Can contribute sweetness but may create suitability issues for patients with lactose intolerance
Microcrystalline cellulose	Filler, compression aid, and structural support	Supports tablet integrity and reduces friability
Povidone	Binder	Controls granule strength and tablet robustness
Sodium starch glycolate	Superdisintegrant	Promotes breakup after chewing or swallowing
Magnesium stearate	Lubricant	Reduces sticking and ejection force; excessive levels can slow wetting and dissolution
Talc	Glidant or anti-adherent	Improves powder flow and manufacturing performance
Flavoring	Taste masking	Critical for acceptability because the tablet is intended to be chewed
Ferrous fumarate	Iron source in the non-hormonal tablets	Creates color, taste, and oxidation-management challenges

The iron-containing tablets require separate development attention. Ferrous salts can produce metallic taste, discoloration, and interaction risks with flavor systems. The iron tablets also create a visual and sensory distinction from the active tablets that can assist day-of-cycle identification.

What excipient strategy is best for a Femcon Fe generic?

The best strategy is a functionally equivalent, taste-optimized immediate-release chewable formulation with a low-risk excipient profile. The formulation should prioritize five performance targets:

1. Rapid disintegration after chewing.
2. Acceptable taste without excessive sweetener or flavor load.
3. Adequate tablet strength during packaging and transport.
4. Low sticking and picking during compression.
5. Dissolution behavior that supports regulatory comparability.

A sponsor should avoid unnecessary excipient complexity. Femcon Fe contains low-dose hormones, so small changes in blend uniformity, segregation, or surface adsorption can affect content uniformity. The manufacturing process must control low-dose active distribution across the batch.

Recommended formulation architecture

A practical formulation platform would use:

• A directly compressible diluent system based on microcrystalline cellulose, mannitol, or a lactose-based blend.
• A co-processed filler to improve mouthfeel and reduce tablet friability.
• A low-level binder such as povidone or a comparable polymer.
• A superdisintegrant selected for rapid breakup without producing a gritty mouthfeel.
• A lubricant system optimized to avoid dissolution retardation.
• A high-intensity sweetener and flavor system validated for hormonal-drug compatibility.
• A film or functional coating only if needed for taste masking, stability, or appearance.

Mannitol may offer a cleaner cooling mouthfeel than lactose and may support a premium chewable positioning. It can raise tablet cost and may require moisture and compression optimization. Isomalt, xylitol, and sorbitol are possible alternatives, but polyol-related gastrointestinal effects and hygroscopicity must be evaluated.

Taste-masking considerations

Taste is the main excipient-driven commercial risk. Hormonal actives are present at low dose, but ferrous fumarate has a recognizable metallic profile. A successful formulation should evaluate:

• Sweetener intensity and aftertaste.
• Flavor persistence after chewing.
• Metallic suppression in ferrous fumarate tablets.
• Tablet grittiness.
• Mouth cooling or chalkiness.
• Flavor stability over shelf life.
• Patient preference across age and cultural groups.

A coated-particle or adsorbate approach could improve taste, but it may complicate bioequivalence and dissolution. A simpler matrix-based formulation is more suitable for a first generic unless the reference product’s sensory profile creates a material barrier to substitution.

What formulations are protected by Femcon Fe?

The principal product concept is a chewable combined oral contraceptive regimen with a separate ferrous fumarate phase. Protection, if any remains enforceable, would depend on specific patents covering composition, dosage form, manufacturing process, packaging, or use. The active ingredients themselves are old and do not create a meaningful new-molecule exclusivity position.

Formulation patent exposure

Potential claim categories include:

• Chewable tablets containing norethindrone and ethinyl estradiol.
• Specific hormone ratios and dose strengths.
• Use of ferrous fumarate as the non-hormonal tablet component.
• Flavoring or taste-masking systems.
• Tablet composition and disintegration characteristics.
• Packaging that distinguishes active and iron tablets.
• Methods of preventing pregnancy using the regimen.

A current patent landscape review should distinguish live U.S. claims from expired patents, abandoned applications, terminal disclaimers, and patents that were never listed in the Orange Book. Product-specific patent status cannot be inferred solely from the brand name or from the age of the product.

What is the FDA and Orange Book status of Femcon Fe?

Femcon Fe was approved as a prescription oral contraceptive under an FDA new drug application. FDA’s Drugs@FDA database and the Orange Book are the controlling sources for approval status, reference-product designation, listed patents, and therapeutic-equivalence information.[2,3]

The commercial status of a branded product can differ from its regulatory status. A product may have an approved application while being discontinued commercially. FDA’s discontinued-drug designation does not automatically mean that all generic development pathways are unavailable.

Regulatory issue	Commercial significance
Approved NDA	Establishes the reference regulatory record
Discontinued marketing	May create an opening for generic or authorized-generic development
Orange Book listing	Determines whether listed patents may create Paragraph IV exposure
Reference-listed drug status	Affects ANDA strategy and bioequivalence planning
Chewable dosage form	Requires dosage-form and performance matching
Ferrous fumarate phase	Requires accurate strength, identity, and regimen presentation

An applicant considering an ANDA should confirm the current reference-listed drug, its marketing status, any FDA suitability-petition history, and all active Orange Book entries before committing to development.

When does Femcon Fe lose exclusivity?

Femcon Fe’s commercial exclusivity is primarily an age-of-product and generic-competition issue rather than a new chemical entity issue. Any original regulatory exclusivity would have expired long ago. Remaining barriers, if present, would arise from active formulation, method-of-use, process, or packaging patents rather than FDA new-drug exclusivity.

The relevant entry questions are:

1. Is the reference product currently listed as the FDA reference product?
2. Does the Orange Book identify active patents?
3. Are the patents expired, disclaimed, or subject to terminal expiration?
4. Does the proposed generic use the same chewable dosage form?
5. Does the applicant need a Paragraph IV certification?
6. Can the applicant obtain bioequivalence using standard pharmacokinetic studies?

A sponsor should not assume that an old brand has no patent risk. It should also not assume that a historical patent creates a current barrier. Both conclusions require a live patent and regulatory record.

What Paragraph IV challenges could affect Femcon Fe?

A Paragraph IV certification would be relevant only if the Orange Book lists an unexpired patent for the reference product and the applicant asserts that the patent is invalid, unenforceable, or not infringed. A Paragraph IV notice can trigger patent litigation and, in some cases, a 30-month stay of approval under the Hatch-Waxman framework.[4]

For Femcon Fe, the likely risk profile is lower than for a recently launched branded drug because the product has an established history and conventional active ingredients. The principal litigation risk would be a later-listed formulation or use patent, not the basic contraceptive composition.

Potential applicant positions could include:

• The patent claims do not cover the proposed excipient system.
• The claims cover a different active ingredient, such as norethindrone acetate rather than norethindrone.
• The claims are expired or terminally disclaimed.
• The proposed product does not practice a claimed manufacturing process.
• The method-of-use claims are not infringed by the approved labeling or use statement.

No current litigation conclusion should be drawn without a current Orange Book and court-docket review.

What commercial opportunities exist for Femcon Fe excipients?

The opportunity is less likely to be a single novel excipient than a differentiated formulation platform. The most attractive commercial paths are below.

1. Premium chewable generic

A sponsor could position a chewable generic around improved taste, lower friability, and easier administration. This approach would compete against standard swallowed tablets and any existing chewable equivalent.

The value proposition is strongest for patients who have difficulty swallowing tablets or prefer a chewable product. The commercial premium would need to offset the added cost of flavor development, sensory testing, and specialized packaging.

2. Lactose-free or low-lactose formulation

Replacing lactose with mannitol, microcrystalline cellulose, or a co-processed excipient could support a lactose-free label claim if the full formulation qualifies. This would create a modest differentiation point, but it would not by itself establish clinical superiority.

The replacement must preserve tablet strength, taste, dissolution, content uniformity, and stability. A lactose-free formulation may also expand contract-manufacturing options where lactose segregation or supplier qualification is a concern.

3. Improved iron-tablet taste system

The ferrous fumarate tablets are a targeted opportunity for coated iron particles, flavor modulation, or a separate sensory design. Better iron-tablet palatability could improve adherence to the 28-day pack, although the sponsor would need to avoid changes that affect iron release or product identification.

4. Simplified manufacturing

A direct-compression process could reduce granulation equipment, solvent exposure, and manufacturing cycle time. The main technical challenge is uniform distribution of low-dose hormones. A sponsor may need ordered blending, geometric dilution, or a premix strategy to control assay variation.

5. Packaging and adherence design

Calendar blister packs, tactile differentiation, and clearer active-versus-iron tablet identification can reduce dosing errors. Packaging improvements may be commercially useful even if they do not create patentable protection.

A connected adherence system could provide a higher-value platform, but it would increase packaging cost and may require separate digital-health validation. The near-term opportunity is a low-complexity calendar pack with strong tablet differentiation.

How strong is the Femcon Fe patent estate?

The basic active-ingredient estate is weak because norethindrone and ethinyl estradiol are established compounds. The defensible value, if any, would sit in narrow formulation, process, packaging, or method-of-use claims.

Patent category	Likely strength for a new entrant
Active ingredients	Low
Conventional tablet excipients	Low
Chewable dosage form	Low to moderate, depending on claim scope and expiration
Specific taste-masking system	Moderate if technically narrow and unexpired
Manufacturing process	Moderate if the process is required or difficult to design around
Packaging and regimen presentation	Low to moderate
Method of contraception	Usually low where the method is old and broadly practiced

The principal barrier is more likely regulatory execution and product economics than blocking patent rights. A generic sponsor should focus on formulation robustness, reference-product access, bioequivalence, and manufacturing cost.

Which companies are challenging or competing with Femcon Fe?

Competition comes from three groups:

1. Generic manufacturers of norethindrone and ethinyl estradiol.
2. Manufacturers of other chewable combined oral contraceptives.
3. Brands using different progestins, estrogen doses, or 24-day active-tablet regimens.

The closest competitor is a product that matches the active ingredients, strength, chewable dosage form, and 21-plus-seven regimen. Products using norethindrone acetate, different estrogen strengths, or non-chewable tablets compete therapeutically but are not direct pharmaceutical equivalents.

A competitive review should compare:

• FDA therapeutic-equivalence rating.
• Availability through wholesalers and retail pharmacies.
• Wholesale acquisition cost and generic discounting.
• Tablet taste and patient reviews.
• Pack format.
• Manufacturer supply reliability.
• Number of active suppliers.
• Contracting with pharmacy benefit managers.

What generic launch risks exist for Femcon Fe?

The main launch risks are:

• Limited commercial demand for an older chewable product.
• Difficulty sourcing or reproducing the reference product.
• Poor taste acceptance.
• Hormone-content variability caused by low-dose actives.
• Dissolution changes caused by lubricants or taste-masking systems.
• Ferrous fumarate discoloration and stability problems.
• Packaging errors between active and iron tablets.
• Limited reimbursement premium for a differentiated chewable formulation.
• Manufacturing costs that exceed conventional oral contraceptive economics.

The launch case improves if the sponsor can use an existing chewable-tablet manufacturing platform, share packaging infrastructure with other oral contraceptives, and obtain reliable active-pharmaceutical-ingredient supply.

Key Takeaways

• Femcon Fe is a chewable norethindrone and ethinyl estradiol contraceptive packaged with seven ferrous fumarate tablets.
• Its commercial differentiation is dosage form and regimen design, not a novel active ingredient.
• The most relevant excipient opportunities are taste masking, lactose replacement, mouthfeel improvement, rapid disintegration, and low-dose blend uniformity.
• Mannitol or co-processed filler systems could support a modernized chewable formulation, but they require careful dissolution and sensory testing.
• Ferrous fumarate creates the most difficult taste, color, and stability issues in the regimen.
• Original FDA exclusivity is no longer the central barrier; current Orange Book patents and regulatory reference-product status determine generic-entry risk.
• The strongest business case is a low-cost, bioequivalent chewable generic with better palatability and reliable calendar packaging.
• A premium formulation has limited value unless the sponsor can demonstrate meaningful patient preference or adherence benefits.

FAQs

Can Femcon Fe be reformulated without lactose?

Yes. Lactose can potentially be replaced with mannitol, microcrystalline cellulose, isomalt, or a co-processed filler. The replacement must preserve assay uniformity, tablet strength, taste, disintegration, dissolution, and stability.

Is ferrous fumarate necessary in a generic Femcon Fe product?

The iron phase is part of the reference-product regimen and must be addressed in an equivalent product strategy. A sponsor cannot assume that omitting or replacing ferrous fumarate is permissible without assessing FDA dosage-form, strength, labeling, and bioequivalence requirements.

Does a chewable Femcon Fe generic require taste testing?

Taste testing is commercially important and may be technically necessary to establish that the product is suitable for its intended administration. The testing should cover both hormonal active tablets and ferrous fumarate tablets.

Can a sponsor patent a new Femcon Fe excipient formulation?

Possibly, if the formulation has novel and non-obvious composition or performance features. Broad claims to ordinary tablet excipients are unlikely to provide strong protection. Narrow claims directed to a specific taste-masking system, stability result, or manufacturing process may be more defensible.

Is Femcon Fe interchangeable with norethindrone acetate and ethinyl estradiol products?

No. Norethindrone and norethindrone acetate are different active ingredients for regulatory purposes. Therapeutic similarity does not establish pharmaceutical equivalence or automatic substitution.

References

1. U.S. National Library of Medicine. (n.d.). Femcon Fe: Norethindrone and ethinyl estradiol, ferrous fumarate tablet labeling. DailyMed. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

4. U.S. Food and Drug Administration. (n.d.). Paragraph IV certification. FDA. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/paragraph-iv-certifications